HOUSTON, Aug. 23, 2023 /PRNewswire/ — KBR (NYSE: KBR) announced today that its Board of Directors has declared a regular quarterly dividend of $0.135 per share on the company’s common stock, par value $0.001 per share, to be paid on October 16, 2023, to stockholders of record on…

New business will bring high quality biosimilar products to market with goal of reducing drug spend and ensuring access to affordable medications Cordavis to launch biosimilar Hyrimoz® with Sandoz beginning in 2024 at more than 80% lower list price than Humira®* WOONSOCKET, R.I., Aug. 23,…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.